Group Structure
Pharmacy, OS, Rx & Labs.
NEUVIOR is structured as a connected pharmaceutical group: PHARMORIS® for medicines intelligence, Rx for supply infrastructure, Labs for applied research and IP, and Pharmacy for frontline delivery and operational learning.
Our divisions
Each division solves a different part of the medicines system while reinforcing the others.
Detail overview
Applied research
NEUVIOR® Labs
Applied research, translational design and protected product architecture for future therapies, workflows and manufacturing adjacencies.
Core Capabilities
- Problem selection and opportunity design
- Feasibility studies and validation plans
- IP development and filing support
- Technical documentation and evidence models
Key Initiatives
Medicines intelligence
PHARMORIS®
The medicines value operating system that helps health systems discover, justify and deploy high-value medicines opportunities.
Core Capabilities
- Opportunity ranking across value, risk and implementability
- Decision-grade evidence packs
- Deployment modelling and value tracking
- Watchlists, provenance and data assurance
- Role-based access and exports
Key Initiatives
Supply infrastructure
NEUVIOR® Rx
The group’s supply and distribution layer, designed to improve medicines access, resilience and execution between sourcing and care delivery.
Core Capabilities
- Procurement and sourcing pathways
- Distribution strategy and operating design
- Shortage-response workflows
- Supplier and route-to-market planning
- Integration with pharmacy and intelligence teams
Key Initiatives
Frontline delivery
NEUVIOR® Pharmacy
Community and patient-facing pharmacy capability that grounds the group in real dispensing, adherence and local operational insight.
Core Capabilities
- Dispensing and operational learning
- Medicines optimisation at point of care
- Patient support and counselling models
- Last-mile service design
- Feedback loops into PHARMORIS® and Rx
Key Initiatives
Division news
September 2025
Innovate UK backs PHARMORIS®
Growth Catalyst – New Innovators validation for the medicines optimisation platform.
29 November 2025
NHS DSPT Standards Met published
Strengthened NHS-facing readiness across information governance and security posture.
5 December 2025
PHARMORIS® trade mark published by IPO UK
UK00004301201 published for software, data analytics and pharmaceutical research service classes.
Q1 2026
ZYLON™ feasibility programme underway
Innovate UK-backed work exploring solvent recovery and bio-intelligent materials for lower-waste pharmaceutical production.
Governance & executive team
Guided by visionary leadership committed to excellence, transparency, and patient-centered innovation.
Varun Cruz
Founder & CEO
Varun Cruz founded NEUVIOR to build a vertically integrated pharmaceutical group spanning AI infrastructure, medicines optimisation, supply, labs and pharmacy.
Chief Scientific Officer
Head of NEUVIOR® Labs
Leading pharmaceutical research and clinical development programs.
Chief Technology Officer
Head of NEUVIOR® OS
Architecting digital health platforms and AI-driven innovation.
Chief Operating Officer
Head of Manufacturing & Operations
Overseeing GMP production and sustainable manufacturing initiatives.
Governance principles
Our structure is designed for traceability, accountability and evidence-led decision-making across product, supply and pharmacy. We prioritize precise claims, strong information governance and regulated-environment discipline.
Accountability
Clear ownership, version control and auditable outputs across teams, products and external communications.
Assurance
Information governance, DSPT credibility and source provenance are treated as operational essentials rather than compliance theatre.
Execution
Strategy, product and operating decisions are sequenced to support safe deployment and credible growth.
Assurance & external validation
Join our mission
We welcome conversations with investors, healthcare partners, and regulatory bodies who share our commitment to pharmaceutical excellence and patient-centered innovation.
Investors
Back a group model that compounds across medicines intelligence,supply ,research and patient-facing operations.
Strategic Partners
Collaborate on product deployment,supply resilience,pharmacy operations or translational research intiatives.
NHS,media & goverance stackholders
Engage with our team on pilots,assurance,product scrutiny and the wider role of pharmaceutical infrastructure.